Bristol-Myers Squibb
 
1Q Revenues: $4.4 Billion (+9%)

1Q Earnings: $1.2 billion (flat)

Comments: Opdivo sales were $704 million in the quarter. Sprycel sales were $407 million, up 9%. Yervoy sales were down 19% to $263 million. Eliquis sales were $734 million in the quarter. Orencia sales were up 19% to $475 million. Revenues include the impact of the transfer of Erbitux and Abilify rights to ImClone and Otsuka, respectively. Hepatitis C Franchise sales were up 62% to $427 million. Reyataz and Sustiva sales were down 25% and 6% respectively.